Lung cancer immunotherapy options expand
Patients and doctors received news this week of the FDA’s approval of the immunotherapy drug pembrolizumab in combination with platinum doublet chemotherapy as first-line therapy for all patients with non-small cell lung cancer, irrespective of patients’ tumor PD-L1 status. The new approval follows the FDA’s decision last November to approve pembrolizumab as a first-line therapy for some […]